We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

54 hedge funds and large institutions have $7.86M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 58 → 54 (-4)

16% less capital invested

Capital invested by funds: $9.31M → $7.86M (-$1.44M)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

Holders
54
Holders Change
-4
Holders Change %
-6.9%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
12
Closed
10
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
-$20K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$330K
2
KCM
Kennedy Capital Management
Missouri
+$314K
3
BC
BIT Capital
Germany
+$223K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$124K
5
CWA
CM Wealth Advisors
Ohio
+$54.8K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$99.1K
2
Two Sigma Investments
Two Sigma Investments
New York
-$92.1K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$84K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$55.6K
5
TSS
Two Sigma Securities
New York
-$54.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.25M – – –
Millennium Management
2
Millennium Management
New York
$1.17M +$330K +16,790 +29%
BlackRock
3
BlackRock
New York
$715K -$99.1K -5,035 -10%
BC
4
BIT Capital
Germany
$566K +$223K +11,323 +45%
KCM
5
Kennedy Capital Management
Missouri
$461K +$314K +15,956 +119%
QPW
6
Quantum Private Wealth
Florida
$359K -$6.77K -344 -1%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$326K – – –
BJL
8
Brighton Jones LLC
Washington
$263K +$1.53K +78 +0.5%
Renaissance Technologies
9
Renaissance Technologies
New York
$200K +$13.1K +665 +6%
LPL Financial
10
LPL Financial
California
$135K +$36.4K +1,850 +28%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$128K -$55.6K -2,824 -25%
State Street
12
State Street
Massachusetts
$127K – – –
Corient Private Wealth
13
Corient Private Wealth
Florida
$118K – – –
IC
14
IEQ Capital
California
$113K – – –
Two Sigma Advisers
15
Two Sigma Advisers
New York
$102K -$84K -4,270 -40%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$98.9K +$124K +6,297 New
Northern Trust
17
Northern Trust
Illinois
$66.5K +$2.75K +140 +3%
Two Sigma Investments
18
Two Sigma Investments
New York
$64K -$92.1K -4,678 -53%
AWM
19
Axxcess Wealth Management
California
$55.2K – – –
Morgan Stanley
20
Morgan Stanley
New York
$52.1K -$5.55K -282 -8%
Mercer Global Advisors
21
Mercer Global Advisors
Colorado
$43K -$2.95K -150 -5%
Envestnet Asset Management
22
Envestnet Asset Management
Illinois
$42.3K – – –
ROTUOC
23
Regents of the University of California
California
$42K – – –
Creative Planning
24
Creative Planning
Kansas
$30.9K – – –
RB
25
Richmond Brothers
Michigan
$30.1K +$37.7K +1,918 New
1
2 3

ONCT Hedge Fund Activity: Q1 2023 in Review

54 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2023, worth a combined $7.86M — down 16% from $9.31M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ONCT and 6 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 10 added.

The largest buyer was Millennium Management, adding an estimated $330K. The largest seller was BlackRock, cutting an estimated $99.1K.

  • 54 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2023, down from 58 in Q4 2022.
  • Funds reported $7.86M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2023, down 16% quarter-over-quarter.
  • 6 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2023 and 10 closed out, a net change of -4 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2023 was Millennium Management, an estimated $330K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2023 was BlackRock, an estimated $99.1K sold.

Based on aggregated 13F filings for Q1 2023.